Imunon Analysis: $13M Raised

Imunon develops innovative medicines that leverage the body's immune system. Their proprietary platforms focus on difficult-to-treat conditions, utilizing immunology and DNA-based technologies. This approach aims to provide transformative therapeutic benefits for patients facing serious health challenges.

Developing anti-cancer therapies using nucleic acid technology; Conducting clinical trials for vaccine development; Partnering with research institutions for innovative solutions; Addressing vaccine-preventable diseases through advanced therapies; Enhancing patient outcomes in oncology and infectious diseases.

Nasdaq listed under IMNN; Leadership team with over 50 years of combined experience; Engaged in clinical trials for ovarian cancer therapies.